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Abstract
Introduction: The clinical efficacy of trastuzumab and taxanes is at least partly related to their ability to mediate or
promote antitumor immune responses. On these grounds, a careful analysis of basal immune profile may be
capital to dissect the heterogeneity of clinical responses to these drugs in patients with locally advanced breast
cancer undergoing neoadjuvant chemotherapy.
Methods: Blood samples were collected from 61 locally advanced breast cancers (36 HER2
- and 25 HER2
+)a t
diagnosis and from 23 healthy women. Immunophenotypic profiling of circulating and intratumor immune cells,
including regulatory T (Treg) cells, was assessed by flow cytometry and immunohistochemistry, respectively. Serum
levels of 10 different cytokines were assessed by multiplex immunoassays. CD8
+ T cell responses to multiple tumor-
associated antigens (TAA) were evaluated by IFN-g-enzyme-linked immunosorbent spot (ELISPOT). The Student’s t
test for two tailed distributions and the Wilcoxon two-sample test were used for the statistical analysis of the data.
Results: The proportion of circulating immune effectors was similar in HER2
+ patients and healthy donors, whereas
higher percentages of natural killer and Treg cells and a lower CD4
+/CD8
+ T cell ratio (with a prevalence of naïve
and central memory CD8
+ T cells) were observed in HER2
- cases. Higher numbers of circulating CD8
+ T cells
specific for several HLA-A*0201-restricted TAA-derived peptides were observed in HER2
+ cases, together with a
higher prevalence of intratumor CD8
+ T cells. Serum cytokine profile of HER2
+ patients was similar to that of
controls, whereas HER2
- cases showed significantly lower cytokine amounts compared to healthy women (IL-2, IL-8,
IL-6) and HER2
+ cases (IL-2, IL-1b, IL-8, IL-6, IL-10).
Conclusions: Compared to HER2- cases, patients with HER2-overexpressing locally advanced breast cancer show a
more limited tumor-related immune suppression. This may account for the clinical benefit achieved in this subset
of patients with the use of drugs acting through, but also promoting, immune-mediated effects.
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Preoperative or neoadjuvant chemotherapy (NC) is cur-
rently considered to be the standard of care for locally
advanced and inoperable breast cancer. One of the main
advantages of this approach is the reduction of tumor
size, which increases the possibility of performing smal-
ler resections of operable tumors with better cosmetic
outcomes [1,2]. Other potential benefits of NC include
an early assessment of response to chemotherapy and
the possibility of obtaining prognostic/predictive infor-
mation, based on the pathologic response to therapy [3].
Although breast cancers that overexpress human epi-
dermal growth factor receptor-2 (HER2) are character-
ized by a poor prognosis [4,5], higher rates of complete
responses are currently achieved in HER2
+ patients by
standard chemotherapy, mainly in association with tras-
tuzumab [6,7], in comparison with HER2
- patients. Like
other monoclonal antibodies used in anticancer therapy,
the activity of trastuzumab is largely dependent on
immuno-mediated mechanisms. In fact, besides trigger-
ing antibody-dependent cytotoxicity (ADCC), trastuzu-
mab also enhances HLA class I-restricted presentation
of endogenous HER2 antigen via the proteasome path-
way, and sensitizes HER2-overexpressing tumors to kill-
ing by MHC class I-restricted HER2-specific cytotoxic
T lymphocytes (CTLs) [7]. Intriguingly, other drugs
used in NC regimens have also been shown to enhance
antigen-specific immune responses in both in vitro and
animal models. In particular, taxanes have immunosti-
mulatory effects against tumor cells and suppress cancer
not only through inhibition of cell division [8,9]. Indeed,
hosts immune functions are highly enhanced after doce-
taxel treatment [10], and paclitaxel plays a positive role
in controlling tumor growth, probably through the
induction of IL-8 [8]. Furthermore, taxanes induce
macrophage-mediated tumor death, stimulate the pro-
duction of pro-inflammatory cytokines (TNF-a,I L - 1 2 ,
and IL-1), and increase lymphokine activated killer
(LAK) cell and natural killer (NK) cell antitumor activity
[10,11].
Given the evidence that tumor cells may be immuno-
genic, more than 60 TAAs have been identified and, as
observed for other tumors, breast cancer cells were also
shown to express TAAs [12,13]. Moreover, convincing
data demonstrate that spontaneous antitumor responses
to TAAs may harness host’s immune system to fight
against cancer, underscoring the need of a retained or
only minimally compromised immunological proficiency
particularly in patients treated with chemotherapeutic
regimens including immunomodulating drugs. Neverthe-
less, only limited information is available on the extent
of spontaneous T cell responses to breast cancer-asso-
ciated antigens in patients with locally advanced tumors.
Considering that breast cancer patients may show
different types and extent of tumor-related immune
dysfunctions [11,14,15], we reasoned that the efficiency
of the host immune system could influence the
responses to current NC regimens. Therefore, in the
present study, we have carried out an extensive immu-
nologic profiling of patients with locally advanced
breast cancer at the time of diagnosis, as a first step
towards a better understanding of the possible role of
antitumor immune responses in mediating the clinical
outcome of NC. The results presented herein demon-
strate that patients with HER2
+ and HER2
- breast can-
c e rh a v ead i f f e r e n tb a s a li m m u n o l o g i cp r o f i l e .I n
particular, our data are consistent with a more limited
tumor-related immune suppression in patients with
HER2-overexpressing tumors, an observation that may
at least in part account for the clinical benefit achieved
in this subset of patients by drugs acting through
immune-mediated effects.
Materials and methods
Patients and healthy donors
Our analysis included 61 patients with histologically
confirmed locally advanced breast carcinoma (defined as
not susceptible of conservative surgery at diagnosis;
UICC, International Union Against Cancer, stage II to
III; Table 1). HER2 status was assessed by immunohisto-
chemistry and chromogenic in situ hybridization (CISH)
or fluorescence in situ hybridization (FISH) in the case
of IHC 2+. All patients had the following clinical fea-
tures: Eastern Cooperative Oncology Group perfor-
mance status of 0 or 1; baseline left ventricular ejection
fraction measured by ultrasonography greater than 50%;
adequate organ function (bone marrow function: neu-
trophils ≥2.0 × 10
9/L, platelets ≥120 × 10
9/L; liver func-
tion: serum bilirubin <1.5 times the upper limit of
normal (ULN), transaminases <2.5 times ULN, alkaline
phosphatase ≤2.5 times ULN, serum creatinine <1.5
times ULN). This study was carried out according to the
ethical principles of the Declaration of Helsinki and
approved by the local ethics committee. All patients
gave written informed consent. Heparinised blood and
sera were also collected from 23 age-matched healthy
women as controls. Patient’s and donor’s HLA genotyp-
ing was performed by PCR sequencing based typing
with primers specific for both locus A and B [16]. Per-
ipheral blood mononuclear cells (PBMCs) were freshly
isolated from heparinised blood of patients or healthy
donors by Ficoll-Hypaque gradient (Lymphoprep, Frese-
nius Kabi Norge Halden, Norway) using standard proce-
dures and viably frozen at -180°C until use. Serum
samples were obtained with blood centrifugation at
2,100 rpm and maintained at -80°C.
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A total of 13 immunogenic HLA-A*0201 nonamer (9-mer)
peptides, derived from different breast cancer-associated
antigens (survivin, mammaglobin-A, HER2, mucin-1,
taxol-resistence associated gene 3, and bcl-XL) were
selected for the study. The HLA-A*0201-restricted Flu
matrix 1 (M158-66) peptide (GILGFVFTL) was used as the
positive control. All peptides were produced by fluorenyl-
methoxycarbonil synthesis (Primm, Milan, Italy) and purity
(>95%) was determined by reverse-phase high-performance
liquid chromatography and verified by mass spectral
MALDI-TOF analysis. Peptides were dissolved in DMSO
at a concentration of 2.5 mg/ml and stored at -70°C until
use. Work stocks for each peptide were prepared in PBS at
a final concentration of 500 μg/ml and stored frozen.
Flow cytometry
The following fluorescent-conjugated monoclonal anti-
bodies were used: a-CD3 fluorescein isothiocyanate
(FITC) or phycoerythrin-texasred (ECD; mouse immu-
noglobulin (Ig) G1, clone UCHT1), a-CD4 phycoery-
thrin-cyanine5 (PC5; mouse IgG1, 13B8.2), a-CD8
phycoerythrin-cyanine7 (PC7; mouse IgG1,
SFCI2IThy2D3), a-CD16 FITC (mouse IgG1, 3G8), a-
CD19 FITC (mouse IgG1 k, J3-119), a-CD25 ECD
(mouse IgG2a, B1.49.9), and a-CD45RA ECD (mouse
IgG1, 2H4LDH11LDB9) all from Beckman Coulter
(Fullerton, CA, USA); a-CD56 phycoerythrin (PE;
mouse IgG1 k, B159) and a-CD197 PE (CCR7, rat
IgG2a k, 3D12) purchased from BD Biosciences (Becton
Dickinson, Franklin Lakes, NJ, USA); a-CD4 PC7
(mouse IgG1 k, RPA-T4), a-CD127 PC5 (mouse IgG1,
eBioRDR5), and a-FoxP3 PE (Rat IgG2a k, PCH101)
from eBioscience (San Diego, CA, USA). Properly
labelled isotypic antibodies were used as negative con-
trols. All antibodies were used in an appropriate volume
of 10% rabbit serum (Dako, Glosdrup, Denmark) and
PBS (Biomerieux, Marcy l’Etoile, France) to reduce non-
specific signal. Intracellular FoxP3 was determined using
the eBioscience FoxP3 Staining Buffer Set (eBioscience,
San Diego, CA, USA) according to the manufacturer’s
instructions. Briefly, after surface molecules staining,
cells were fixed and permeabilized with fixation/permea-
bilization buffer for 30 minutes at 4°C, washed twice,
and labelled with FoxP3 antibody in the presence of 2%
rabbit serum in PBS at 4°C for at least 30 minutes and,
after two washes, cells were re-suspended in PBS with
1% paraformaldehyde. At least 5 × 10
4 cells for surface
markers and 1 × 10
6 cells for intracellular staining were
acquired. Cytofluorimetric analysis was performed with
a Cytomics FC500 (Beckman Coulter, Fullerton, CA,
USA) and data were analyzed with CXP software (Beck-
man Coulter, Fullerton, CA, USA).
IFN-g ELISPOT assay
The interferon (IFN)-g release enzyme-linked immuno-
sorbent spot (ELISPOT) assay was performed using a
commercial kit (Human IFN gamma ELISPOT; Thermo
scientific, Rockford, IL, USA), according to manufac-
turer’s instructions. The assay was carried out using
autologous peptide-pulsed monocytes as antigen pre-
senting cells (APCs) and isolated CD8
+ T lymphocytes
as responders. Monocytes, isolated by a two hour plastic
adherence step from patient’s PBMCs, were loaded with
10 μg/ml of each 9-mer peptide in complete medium,
supplemented with 5 μg/ml of human b2-microglobulin,
and incubated for two hours at 37°C with 5% CO2. Puri-
fied effectors were obtained by immunomagnetic enrich-
ment protocols using the human CD8
+ T cell isolation
kit II (Miltenyi Biotec, Bergisch Gladbach, Germany),
Table 1 Patients’ characteristics
Characteristic
Mean age, years 44.7 46.3
Range 23-70 32-67
Hormone receptor status
1
ER+ and PgR+ 6 23
ER+ and PgR- 4 5
ER- and PgR- 13 7
ER- and PgR+ 2 1
HER2/neu
0-1 27
2+ 9
CISH/FISH not amplified 9
CISH/FISH amplified /
3+ 25
Tumor size
T2 18 (2 multifocal) 26 (2 multifocal)
T3 7 (1 multifocal) 10 (1 multifocal)
Clinical lymph node involvement
N + 23 23
N- 2 1 3
Histotype
ductal 24 26
lobular / 7
others 1 3
Grading
2
G1 / /
G2 4 18
G3 17 15
G(x) 1
NA 4 2
1 Hormone receptor status is significantly different between HER2+ and HER2-
patients, with HER2-overexpressing cancers being mostly ER- and PgR- (P =
0.01).
CISH, chromogenic in situ hybridization; ER, estrogen receptor; FISH,
fluorescence in situ hybridization; HER-2, human epidermal growth factor
receptor-2; PgR, progesterone receptor.
2 Grading is significantly different between the two cohorts of patients: HER2+
patients are mainly G3, while HER2- patients are mostly G2 (P = 0.01).
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(50,000 cells/well) at 1:1 effector:target ratio. FLU
M158-66 and unstimulated monocytes were used as
positive and negative controls, respectively. Cells were
seeded onto ELISPOT capture plates in triplicates and
incubated for 48 hours at 37°C with 5% CO2.A l lp l a t e s
were evaluated by a computer-assisted ELISPOT reader
(Eli.Expert, A.EL.VIS GmbH, Hannover, Germany). The
number of spots in negative control wells (range of 0 to
5 spots) was subtracted from the number of spots in sti-
mulated wells. Responses were considered significant if
a minimum of five IFN-g producing cells were detected
in the wells.
Cytokine detection
Levels of IL-1a,I L - 1 b, IL-2, IL-6, IL-8, IL-10, IL-12p70,
TNF-a, and granulocyte macrophage colony-stimulating
factor (GM-CSF) were evaluated using the SearchLight
®
multiplex arrays (Food and Drug Administration
approved, Aushon Biosystems, TEMA Ricerca, Bologna,
Italy) according to the manufacturer’s instructions. Briefly,
custom human 8-plexarray and human 1-plexarray (for
GM-CSF detection) with pre-spotted cytokine-specific
antibodies were used. Standards or pre-diluted samples
were added in duplicate and, after one hour of incubation
at room temperature and three washes, biotinylated anti-
body reagent was added to each well. After 30 minutes
incubation at room temperature and three washes, block
solution was added to stabilize the signal. The addition of
Streptavidin-HRP Reagent and SuperSignal
® Substrate,
and the acquisition of luminescent signal with a cooled
CCD (Charge Coupled Device) camera, together with data
analysis and processing, were performed by TEMA Ricerca
laboratories’ customer service (Bologna, Italy).
Transforming growth factor (TGF)-b1 serum levels were
assessed through DRG TGF-b1 ELISA (DRG Instruments
G m b H ,M a r b u r g ,G e r m a n y )u nder instructions. Pre-
diluted samples and standards underwent appropriate
acidification and neutralization before testing. Briefly, pre-
treated standards, controls and samples were dispensed
into wells in duplicate and plates were incubated overnight
at 4°C. After three washes, antiserum was added to wells
and incubated for 120 minutes at room temperature, plate
was rinsed three times and anti-mouse biotin (enzyme
conjugate) was dispensed and incubated for 45 minutes.
After three washes, enzyme complex was added to wells,
then plates were incubated 45 minutes and washed three
times. After the addition of substrate solution for 15 min-
utes, the reaction was stopped and the adsorbance at 450
± 10 nm was determined with a microtiter plate reader
(Bio-Tek Instruments, Winooski, VT, USA). As there is an
extremely variable range of normal values reported in the
literature, healthy women serum levels were taken as
references.
Immunohistochemistry
Considering that the diagnostic biopsy is not fully repre-
sentative of the whole tumor mass, the lymphoid infiltrate
was investigated in 40 primary advanced breast carcino-
mas from a separate series of patients who underwent sur-
gical resection during the past decade at our institution.
Twenty cases were HER-2
+ (3+) and 20 HER-2
- (0 or 1+).
All specimens were routinely fixed in 10% buffered forma-
lin, embedded in paraffin and then stained with H&E for
histological examination. For immunohistochemical ana-
lyses, 2 to 3 µm serial sections of primary tumors were
processed with automated immunostainer Benchmark XT
(Ventana, Tucson, AZ, USA), and staining was carried out
with the following antibodies: CD8 (clone SP57, Ventana
Medical System, Tucson, AZ, USA); FoxP3 (clone 259D/
C7, BD Pharmingen, Franklin Lakes, NJ, USA) diluted
1:100 e TiA-1 (clone TiA-1, Bioreagents, Golden, CO,
USA) diluted 1:100. Nuclear counterstaining was accom-
plished with Harris’ hematoxylin. Omission of the primary
antibody was used as a negative control. The results for
staining were evaluated with reference to the number of
unequivocally stained lymphoid cells. Ten randomly cho-
sen representative microscopic fields were counted at 40x
original magnification.
Statistical analysis
Chi-square test was used to compare hormone receptor
(HR) expression and grading within HER2
- and HER2
+
populations. Data obtained from multiple independent
experiments were expressed as mean and standard devia-
tion for immunophenotypic analysis and ELISPOT assays;
cytokine box plots were obtained with SigmaPlot. The Stu-
dent’s t test for two tailed distributions and the Wilcoxon
two-sample test were used for the statistical analysis of the
data. Odds ratio and 95% confidence intervals in multivari-
ate analysis were performed to assess the possible influence
of clinico-pathological variables on the immunological cor-
relations observed: immunological variables (cytokine
levels) were divided into quartiles according to their con-
centrations and then stratified for HR expression (estrogen
receptor (ER)- progesterone receptor (PgR)- and ER+ and/
or PgR+), and tumor grading (G2 or G3). Wilcoxon rank-
test was used to compare the distribution of intratumor
CD8
+ and FoxP3
+ cells between HER2
+ and HER2
- cases.
Results were considered to be statistically significant when
P ≤ 0.05 (two-sided).
Results
HER2
+ and HER2
- patients exhibit a different distribution
of circulating and intratumor immune cells
The distribution of different circulating immune popula-
tions was investigated at diagnosis by multiparametric
flow cytometry comparing 17 women with HER2-over-
expressing cancers, 20 women with HER2
- tumors, and
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significantly lower percentage of CD3
+ T cells (Figure
1c) was observed in HER2
- patients with respect to both
HER2
+ cases (P = 0.028) and controls (P = 0.0003). In
parallel, among the CD3
- cell populations, higher num-
bers of CD16
+CD56
+ NK cells were detected in HER2
-
cases compared with HER2
+ patients (P = 0.049) and
healthy donors (P = 0.025; Figure 1a). Interestingly, no
major difference in the distribution of circulating CD3
-
cells was observed between HER2-overexpressing
patients and controls. The percentage of B cells (Figure
1b) was not significantly different among the three
groups investigated, even if HER2
- (n = 14) patients
showed slightly higher numbers of CD3
-CD19
+ cells
than HER2
+ patients (n = 15) and donors (n = 13; P =
0.07).
When the CD3
+ population was considered separately,
HER2
- patients showed significantly higher percentages
of CD8
+ Tc e l l s( P =0 . 0 2 8 ;d a t an o ts h o w n )a n da
lower CD4
+/CD8
+ ratio (Figure 1d; P = 0.046) when
compared with HER2
+ cases. Because of the different
contribution of memory subsets in mediating antitumor
immune responses [17-19], the differentiation state of T
cell was investigated through the combined analysis of
the chemokine receptor CCR7 and the CD45RA iso-
form, to distinguish CCR7
+CD45RA
+ naïve, CCR7
+CD45RA
- central memory (CM), CCR7
-CD45RA
- effec-
tor memory (EM), and CCR7
-CD45RA
+ terminally dif-
ferentiated (Temra) cells [20]. Although the three
studied groups showed a similar distribution of memory
CD3
+ T cell subsets (not shown), separate analysis of
the CD4
+ and CD8
+ compartments disclosed remarkable
differences. In fact, compared with controls, HER2
+
patients carried a higher percentage of CM CD4
+ T
cells (P =0 . 0 0 3 ) ,w h e r e a sH E R 2
- cases showed signifi-
cantly higher numbers of CM CD8
+ T lymphocytes (P =
0.022). Moreover, a higher percentage of EM CD4
+ cells
(P = 0.023), at the expense of the CM subset (P =
0.023), was found in HER2
- cases compared with HER2
+
patients (Figure 1f). Finally, the two groups of breast
cancer patients showed a completely different memory
sharing among CD8
+ cells, with a prevalence of naïve (P
= 0.002) and CM cells (P =0 . 0 0 5 )i nH E R 2
- cases and
higher percentages of EM (P = 0.005) and Temra cells
(P = 0.012) in HER2
+ patients.
Several studies argued the unfavorable involvement of
circulating regulatory T cells (Tregs) in cancer progres-
sion, demonstrating the presence of increased numbers
of CD4
+CD25
highFoxP3
+ especially in metastatic cancers
[21]. Considering that this immunophenotypic charac-
terization is unsuitable for uniquely defining this specia-
lized T cell subset, we used IL-7 receptor (CD127)
down-regulation as a further feature indicative of sup-
pressive functions [22] and identified Tregs as CD4
+CD25
highCD127
lowFoxP3
+ cells. The analysis showed
that total numbers of so determined Tregs were not sig-
nificantly different between patients and controls.
Nevertheless, considering the two groups of patients
separately, HER2
- exhibited a significantly higher per-
centage of circulating Treg cells (P = 0.02) when com-
pared with healthy donors (Figure 1e).
Characterization of the lymphoid infiltrate in an unre-
lated series of locally advanced breast cancers disclosed
a significantly higher prevalence of intratumor CD8
+ T
cells in HER2
+ cases (median 1000, range: 730 to 1880)
as compared with the HER2
- subgroup (median 234,
range: 117 to 890, P = 0.04). TiA-1
+ cells were also
more abundant in HER2
+ tumors and only rarely
detected in the HER2
- subgroup (not shown). Conver-
sely, the median numbers of FoxP3
+ cells was higher in
HER2
+ cases (170, range: 50 to 508) than in HER2
-
tumors (25, range: 10 to 108, P = 0.04; Figure 2).
HER2
+ patients display enhanced CD8
+ T cell responses
to different TAA-derived epitopes compared with both
HER2
- patients and healthy donors
Spontaneous CD8
+ T cell responses to 13 TAA-derived
peptides (Her2, muc-1, mam-A, trag-3, survivin, bcl-xL;
Table 2) were evaluated by IFN-g ELISPOT assay in six
HER2
+ and seven HER2
- HLA-A*0201
+ patients and five
HLA-A*0201
+ age-matched healthy women. IFN-g-
secreting CD8
+ T cells were detected in all samples (Fig-
ure 3), although higher numbers of CD8
+ T cells speci-
fic for all epitope peptides investigated were observed in
both HER2
+ and HER2
- patients compared with healthy
donors (both P<0.002). Notably, the number of circulat-
ing TAA epitope-specific CD8
+ T cells was higher in
HER2
+ cases compared with HER2
- (P<0.005), particu-
larly against peptides derived from trag-3, muc-1, and
bcl-xL (Figure 3). Empty monocytes were considered as
negative controls and the number of spots was usually
at the background level (<10 SFC/50,000 CD8
+ cells).
No significant differences were found between patients
and donors against Flu M1 GIL58-66 peptide, used as
positive control (49<SFC/50,000 CD8+ cells>76), and
similar levels of responses were also observed against
PHA (167<SFC/50,000 CD8+ cells>221), confirming a
retained T cell responsiveness.
HER2
+ patients show similar serum cytokine profile in
respect to donors
The serum levels of 10 different cytokines were evalu-
ated in all 61 patients and 23 healthy women, consid-
ered as internal reference values. No significant
difference was observed when comparing the global
cohort of patients with controls. However, when breast
cancer patients were considered as two different groups
based on HER2 expression, the comparison revealed
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Page 5 of 13Figure 1 Immunophenotypic characterization of peripheral blood lymphocytes. Percentages of (a) natural killer cells (NK; CD3
-CD16
+CD56
+;
neg = 20, pos = 17, ctrl = 17), (b) B cells (CD3
-CD19
+; neg = 14, pos = 15, ctrl = 15), (c) T lymphocytes (CD3
+CD19
-; neg = 20, pos = 17, ctrl =
17), (d) CD4
+/CD8
+ ratio (CD3
+CD4
+/CD3
+CD8
+; neg = 20, pos = 17, ctrl = 17), and (e) regulatory T cells (Treg; CD3
+CD4
+CD25
highCD127
lowFoxP3
+; neg = 20, pos = 15, ctrl = 17) assessed in HER2
- (neg), HER2-overexpressing (pos) patients and age-matched healthy
women (ctrl). (f) Differentiation (memory) status of CD3
+CD4
+ and CD3
+CD8
+ lymphocytes was investigated through CCR7 and CD45RA
expression (neg = 12; pos = 10; ctrl = 10). Statistical analysis was performed with t Student test. *, P<0.05 (refer to text for exact P value). HER-2,
human epidermal growth factor receptor-2.
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- patients carried significantly lower amounts
of IL-2 (P = 0.0222), IL-8 (P = 0.009), and IL-6 (P =
0.016) with respect to donors (Figure 4), whereas the
cytokine profile of HER2
+ cases was almost superimpo-
sable to that of healthy women (Figure 4). Notably, the
most evident differences emerged from the comparison
between the two groups of patients, with HER2
- cases
showing significantly reduced levels of IL-2 (P =
0.0229), IL-1b (P = 0.0207), IL-8 (P =0 . 0 0 7 ) ,I L - 6( P =
0.0001), and IL-10 (P = 0.0247; Figure 4), independently
by other clinical-pathological parameters such as HR
expression and tumor grading (P-trend in multivariate
analysis: IL-1b P = 0.002, IL-2 P = 0.004, IL-6 P =
0.004, IL-8 P = 0.02, IL-10 P = 0.02; Table 3). No differ-
ences were found in IL-1a,T N F - a, IL-12p70, GM-CSF,
and TGF-b serum concentrations.
Discussion
Evidence accumulated so far indicates that the immune
system can influence the initiation and development of
cancer and it is widely believed that T lymphocytes
represent the most potent antitumor effector cells. In
this respect, there is an urgent need to develop thera-
peutic approaches able to preserve or only minimally
impair immune functions since ADCC-promoting thera-
peutic antibodies, such as trastuzumab, and cancer vac-
cines are being increasingly used as adjuvant and
neoadjuvant treatment modalities [23]. Furthermore,
also the therapeutic efficacy of some “conventional”
drugs, such as doxorubicin and paclitaxel, involves
immunomediated mechanisms [11,24]. On these
grounds, we considered it clinically relevant to exten-
sively investigate at diagnosis the immunological profile
of locally advanced breast cancer patients who are can-
didates for NC including immunomodulating drugs. The
present study provides baseline immunological data that
may constitute a reference for an informative monitor-
ing of immune responses during NC (ongoing study).
Provided the feasibility of monitoring antitumor
responses during therapy and considering that sera from
breast cancer patients should represent a valuable dis-
covery tool to identify potential targets involved in
breast cancer progression [25], we focused mainly on
peripheral blood as the easiest accessible way to detect
and measure immune-changes.
It is worth considering that most studies reporting
analyses of systemic immunologic parameters in breast
cancer patients included extremely variable series of
cases, thus obtaining wide ranges of values and often
conflicting results. Our study does not suffer from this
limitation, being based on a relatively homogeneous
group of patients including only locally advanced can-
cers and excluding metastatic patients, which are the
main contributors to outliers [26,27].
Previous data reported a significant increase in circu-
lating B lymphocytes and NK cells in breast cancer
patients in comparison with control groups [14], with a
lower total number of T lymphocytes [15]. Interestingly,
in our study, HER2
+ patients retained a normal distribu-
tion in NK cells, and T and B lymphocytes if compared
with healthy donors, whereas HER2
- cases displayed
lower percentages of T cells and higher numbers of NK
and, to a lesser extent, of B cells. The increased NK cell
numbers and activity reported in pre-treated patients
Figure 2 Composite figure showing CD8 and FoxP3 expression
in lymphoid cells infiltrating representative HER2
- or HER2
+
breast carcinomas.( a) Few CD8
+ cells are present within the
tumor, and infiltrate tumor nests in a HER2
- case. (b) Some FoxP3
+
cells infiltrate a HER2
- breast carcinoma. (c) CD8
+ cells are numerous
and surround tumoral cords in a HER2
+ breast carcinoma. (d)
Higher numbers of FoxP3
+ cells infiltrate a HER2
+ case. (a to d)
Immunohistochemical stain; paraffin section; Hematoxylin
counterstain; (a and c) 20× original magnification, (b and d) 40×
magnification. HER2: human epidermal growth factor receptor-2.
Table 2 Library of immunogenic peptide epitopes used
to evaluate CD8+ T cell responses to breast-cancer-
associated antigens
Mammaglobin-A LIY83-92 LIYDSSLCDL 34
Trag-3 HAC37-45 HACWPAFTV 35
SIL57-66 SILLRDAGLV 35
Survivin ELT95-104 ELTLGEFLKL 36
LDR104-113 LDRERAKNKI 36
Mucin-1 LLL12-20 LLLLTVLTV 33
STA950-958 STAPPVHNV 33
Bcl-xL RIA165-174 RIAAWMATYL 13
YLN173-182 YLNDHLEPWI 13
Her2/neu KIF369-377 KIFGSLAFL 12
CLT789-797 CLTSTVQLV 12
VLV851-859 VLVKSPNHV 12
ELV971-979 ELVSEFSRM 12
HER-2, human epidermal growth factor receptor-2; Trag-3, taxol-resistance
associated gene 3.
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Page 7 of 13were related to time to treatment failure [14] and were
proposed to be the result of activation of the innate
immunity by the tumor or dependent on a defective reg-
ulation of NK cells in these patients [28]. Conversely,
Dewan and colleagues observed significantly lower NK
cell activity in PBMC from breast cancer patients, as
compared with that of healthy individuals. Intriguingly,
this defect was more pronounced in HER2
- breast can-
cer patients [15], suggesting an underlying NK dysfunc-
tion in this subgroup. Further, we noticed that HER2
+
patients showed an increased CD4/CD8 ratio with
respect to HER2
- cases, a feature previously associated
with a better chance of responding to NC [14]. How-
ever, opinions regarding which T-cell subset provides
the best tumor protection, especially among memory
sub-populations, are still controversial. Indeed experi-
mental evidence suggests that central (TCM) and effector
(TEM) memory T cells can each confer a protective
advantage [17-19], with TCM providing a reservoir of
antigen-specific T cells, ready to expand and replenish
the periphery upon secondary challenge, and TEM dis-
playing a more activated phenotype capable of granzyme
B and perforin expression, IFN-g secretion, and tumor-
specific killing in vitro [17]. Compared with healthy
donors, our data disclosed a higher percentage of CD4
+
TCM (CCR7
+CD45RA
-)i nH E R 2
+ patients and higher
numbers of CD8
+ TCM in HER2
- cases. This observation
may suggest the existence, in both groups, of an active,
though predominantly memory T-cell driven, antitumor
response which may benefit and respond to recall anti-
gens from a cancer vaccine. Interestingly, in our study
the main variations in memory subsets distribution were
found between HER2
- and HER2
+ patients. Although
the CD4
+ T cell population of HER2
+ cases disclosed a
favorable shift to the TCM phenotype, in these same
patients CD8
+ T lymphocytes revealed a predominance
of TEM and terminally differentiated cells. In contrast,
HER2
- patients exhibit mainly CCR7
+ CD8
+ T cells
(naïve and TCM). It should be considered that peripheral
CD8
+ T cells expressing effector functions against viral
[29,30] or tumor antigens [31] are almost uniformly
CCR7
- and are endowed with full effector capacities, far
greater than naïve or TCM cells. Moreover, as the differ-
entiation to terminal effector cells is related to increased
Figure 3 CD8
+ T cell responses to multiple breast cancer-associated antigenic epitopes assessed by IFN-g-ELISPOT (interferon-g-
Enzyme Linked Immunosorbent Spot). All tests were performed using CD8
+ purified T cells as effectors and autologous peptide-loaded
monocytes as antigen presenting cells (APCs; effector:target ratio of 1:1). The number (enumerated as SFC, spot forming cells) of TAA-specific (or
FluM1-specific, flu matrix protein1-derived epitope) circulating CD8
+ T cells was investigated in HER2
- (neg = 7) and HER2
+ (pos = 6) breast
cancer patients, whereas antigen-specific responses of healthy women were used as controls (ctrl = 5). PHA-loaded and empty monocytes
(EMPTY MONO) were used as positive and negative controls, respectively. For peptides amino acid sequences, refer to Table 2. HER-2, human
epidermal growth factor receptor-2; TAA, tumor-associated antigens.
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Page 8 of 13Figure 4 Serum cytokine profile. Interleukin (IL)-2, IL-12p70, IL-1a, IL-1b, IL-8, IL-6, IL10 (neg = 36, pos = 25, ctrl = 23), Tumor necrosis factor-a
(TNF-a; neg = 33, pos = 23, ctrl = 23), granulocyte-macrophage colony-stimulating factor (GM-CSF; neg = 33, pos = 23, ctrl = 19) and
transforming growth factor-b (TGF-b; neg = 27, pos = 21, ctrl = 9) levels were evaluated in serum samples from HER2
- (neg), HER2
+ (pos)
patients and age-matched healthy women (ctrl). Statistical analysis was performed with the Wilcoxon two-sample test. *, P<0.05 (refer to text for
exact P value). HER2, human epidermal growth factor receptor-2.
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Page 9 of 13cytolytic potential of CD8
+ T cells, we hypothesize that
the extent of maturation might be due to an effective
antitumor response [18].
Pre-existing T cell responses to TAA have been
reported in patients with solid tumors [32]; however,
these responses usually involve a low frequency of anti-
gen-specific T cells, not detectable in the majority of
patients [18]. In this regard, literature data on circulat-
ing tumor antigen-specific T cells in breast cancer
patients are still conflicting, probably because of the pre-
dominant focus on single epitopes [18]. Circulating T
cells able to recognize CD8
+ epitopes of HER2 [12],
MUC-1 [33], mammaglobin-A [34], Trag-3 [35], survivin
[36], or bcl-xL [13] have been described in distinct
papers, but the evaluation of multiepitopic antitumor
responses is still lacking. We therefore assessed the
amount of IFN-g-secreting CD8
+ T cells specific for a
broad spectrum of HLA-A*0201 peptides derived from
Her2, muc-1, mam-A, trag-3, survivin, and bcl-xL. Nota-
bly, we found increased IFN-g release to all screened
epitopes in the global cohort of patients if compared
with healthy donors, demonstrating the existence of
spontaneous T cell responses against multiple TAA in
locally advanced breast cancer patients. The ability to
stimulate the generation of antitumor CD8
+ T cells
seemed to be more pronounced in HER2
+ cancers, espe-
cially towards Her2-, trag-3-, muc-1-, and bcl-xL-derived
epitopes. This peculiarity m a yb eu s e f u li nt h ed e s i g n
and optimization of vaccine strategies, which could take
advantage of host’s pre-existing antitumor immune
response. Moreover, the increased numbers of TAA-spe-
cific circulating CD8
+ T cells characterizing HER2
+
patients may positively contribute to the clinical efficacy
of trastuzumab, which is able to sensitize HER2-overex-
pressing tumors to the killing by HER2-specific CTLs
[7], and may enhance the antigen-specific immune
responses promoted by doxorubicin and paclitaxel [37].
Our findings at the systemic level are also consistent
with the demonstration of a significantly higher preva-
lence of CD8
+ T lymphocytes infiltrating HER2
+ tumors
that could contribute to a better clinical outcome [38].
This suggests that HER2 overexpression may be asso-
ciated with enhanced immunogenicity of tumor cells
and/or with a less immunosuppressive microenviron-
ment. Further characterization of the activation state of
lymphocytes infiltrating these tumors is, however,
required to draw definitive conclusions in this respect.
It is well recognized that tumors may down-regulate
t h ei m m u n er e s p o n s et ot u m o ra n t i g e n sb yi n d u c i n g
several immune suppressor mechanisms, including Treg
recruitment. Increased numbers of Tregs have been cor-
related with greater disease burden and poorer overall
survival [39]. In particular, Treg cells are augmented in
the peripheral blood and within the tumor microenvir-
onment in patients with breast carcinomas [40]. Our
analysis of FoxP3 expression in intratumor lymphocytes
disclosed significantly higher prevalence of FoxP3
+ cells
in HER2
+ tumors. This may be a homeostatic
Table 3 Odds ratio (OR) and 95% confidence interval (CI) adjusted for hormone receptor expression and tumor
grading according to cytokines levels in HER+ and HER- patients
Cytokines level quartiles
1
1-low 2 3 4-high P trend
IL-1b
N. pos/neg
2 4/11 5/10 5/10 11/5
OR (95% CI) 1
3 6.3 (0.7-53.2) 33.6 (2.3-494.6) 55.4 (4.1-746.0) 0.002
IL-2
N. pos/neg
2 3/12 6/9 6/10 10/5
OR (95% CI) 1
3 15.7 (1.6-150.5) 10.3 (1.2-92.4) 31.8 (3.5-289.6) 0.004
IL-6
N. pos/neg
2 2/15 5/9 7/8 11/4
OR (95% CI) 1
3 3.8 (0.5-31.0) 8.2 (1.0-65.4) 21.9 (2.6-185.8) 0.004
IL-8
N. pos/neg
2 2/14 6/9 8/7 9/6
OR (95% CI) 1
3 3.7 (0.5-26.0) 5.6 (0.7-42.3) 11.7 (1.4-95.5) 0.02
IL-10
N. pos/neg
2 6/11 3/9 5/10 11/4
OR (95% CI) 1
3 0.3 (0.04-2.6) 1.6 (0.2-12.1) 9.6 (1.5-59.0) 0.02
1Quartiles were: IL-1b: ≤0.5/0.6-1.7/1.8-4.2/≥4.3; IL-2: ≤2.2/2.3-5.8/5.9-15.8/≥15.9; IL-6: ≤1.6/1.7-3.4/3.5-6.5/≥6.6; IL-8: ≤1.7/1.8-3.7/3.8-6.2/≥6.3; IL-10: ≤0.4/0.5-1.4/1.5-
3.3/≥3.4 pg/ml.
2 pos, HER2+; neg, HER2-;
3 Reference category.
HER-2, human epidermal growth factor receptor-2; IL, interleukin.
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Page 10 of 13consequence of the higher content of infiltrating CD8
+
T cells detected in these cancers, or may reflect an
active local recruitment of Tregs. It is worth considering
in this respect that conflicting results have been
reported with regard to Treg frequencies in HER2
- ver-
sus HER2
+ breast cancers [27,41], discrepancies that
could be due in part to tumor staging, but also to the
different and often partial phenotypic markers used to
identify regulatory T cells. This suppressor cell subset is
often identified as CD4
+CD25
high cells [27] or as CD4
+FoxP3
+ lymphocytes [41], even if these markers are
unable to uniquely define a regulatory T cell phenotype.
Therefore, the use of FoxP3 as a single immunohisto-
chemical marker to identify Tregs may have overesti-
mated the number of Tregs in the HER2
+ subgroup. In
fact, this approach can not discriminate true FoxP3
+
Treg cells from T lymphocytes activated by local stimuli
and therefore transiently expressing FoxP3 without
being endowed of immunosuppressive functions. To
overcome these limitations, we have bona fide consid-
ered as circulating Tregs only cells expressing the CD4
+CD25
highCD127
lowFoxP3
+ phenotype, as the down-reg-
ulation of the IL-7 receptor (CD127) is associated with
suppressive functions [22]. This extended phenotypic
definition did not disclose significant differences in Treg
distribution between the whole group of breast cancer
patients and controls, but it revealed higher numbers of
circulating Tregs in HER2
- patients with respect to
donors. Tregs exert their suppressor activity by inhibit-
ing T cell proliferation, NK cell-mediated cytotoxicity
[42], and TAA-specific immunity [43]. On these
grounds, the nearly physiological number of circulating
Tregs displayed by stage II and III HER2
+ breast cancer
patients may imply a favorable background for NK-
involving therapy such as monoclonal antibodies (trastu-
zumab), and may further benefit from the spontaneous
enhanced antitumor T cell responses.
The likely retained immune proficiency of HER2
+
patients is supported by an apparently unchanged cyto-
kine profile, as sharpened by the comparison with
serum cytokine levels of healthy women, which displays
no significant differences. It is widely accepted that solid
tumors are associated with a pathologic shift toward the
T-helper type 2 cytokine pattern; whereas T-helper 1-
induced inflammation inhibits tumor growth. In breast
cancer patients, depressed serum levels of IL-2, GM-
CSF, IFN-g and enhanced TNF-a and IL-6 amounts
were reported in comparison with controls [11] and
some of these immune dysfunctions are also present in
early-stage tumors. In our study, we noticed significantly
lower levels of IL-2 and IL-8, but also of IL-6 in HER2
-
patients with respect to healthy women. Increased
s e r u ml e v e l so fI L - 6w e r ep r e v i o u s l yr e p o r t e di np r o -
gressive recurrent breast cancer patients [44], especially
in the presence of metastasis [26], conversely no meta-
static cases were enrolled in our cohort. Interestingly,
the comparison of cytokine layouts between HER2
- and
HER2
+ patients disclosed pathogenically relevant differ-
ences between the two groups. In particular, HER2
-
patients showed lower levels of IL-2, previously asso-
ciated with relapse of the disease [45,46], reduced
amounts of the pro-inflammatory cytokines IL-1b and
IL-6 (repressors of in vitro cell cycle progression) [47],
and reduced levels of IL-8, recently reported also in the
in vitro comparison of HER2
- and HER2
+ breast cancers
cell lines and in serum samples from metastatic breast
cancer patients [25]. Finally, the pleiotropic cytokine IL-
10, which may exert tumor-promoting activity or con-
siderable antitumor effects, at low and high concentra-
tions, respectively [46], was detected at lower amounts
in HER2
- patients. On the other hand, the higher levels
of IL-2 in HER2
+ patients may be consistent with an
activation of T cells by TAA-derived peptides [48].
Notably, the differences in the cytokine levels observed
between HER2
- and HER2
+ cases were independent of
the clinical-pathological features showed by the two
cohorts of patients (Table 3).
The different immunologic profile of patients with
HER2
- and HER2
+ tumors highlights the importance of
considering them as two distinct populations not only
with regard to tumor characteristics, but also concerning
their immune status. Our analysis, however, may show
some limitations mainly due to the quite large number
of immunological factors considered. This multipara-
metric approach has considerably restricted the global
case series, thus limiting the possibility to make compar-
isons of adequate statistical power between subpopula-
tions of HER2
- and HER2
+ patients. Larger series should
be therefore investigated to conclusively rule out the
possible influence of distinct clinico-pathological vari-
ables on the immunological correlations observed.
Moreover, the research of TAA memory T-cell
responses was confined at the peripheral immune com-
partment; an in situ comparative survey is needed to
confirm our data. An interesting issue that needs further
investigation is the assessment of whether the higher
percentage of effector memory CD8
+ T cells observed in
HER2
+ patients correlates with the enhanced response
against TAA noticed in this population. In perspective,
therefore, the characterization of relevant immune para-
meters may also have a prognostic value, as recently
emphasized by the finding that a decreased expression
of immune response-associated genes was associated
with poor prognosis, particularly in HER2
+ cases [49].
Accordingly, the apparently preserved immunological
capacity of HER2
+ patients may constitute a favorable
milieu for several immune system-based therapies. In
this respect, a detailed characterization of the
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Page 11 of 13immunological profile at diagnosis may be useful to
individualize the most promising therapeutic choice or
to further contribute in the therapeutic schedule’s
design. Furthermore, since some chemotherapeutic
drugs display beneficial effects on host immune func-
tions [11,50], our results suggest that a careful immune-
monitoring of breast cancer patients during NC may be
useful to predict the response to therapy and to obtain a
better prognostic definition.
Conclusions
In conclusion, our data indicate that, compared with
HER2
- cases, patients with HER2-overexpressing, locally
advanced breast cancer show a more limited tumor-
related immune suppression. This may account for the
clinical benefit achieved in this subset of patients with
the use of drugs acting through immune-mediated
mechanisms. These findings also provide the rationale
for further studies aimed at assessing the possible pre-
dictive and/or prognostic role of immune markers in
locally advanced breast cancer patients undergoing NC.
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